Abstract Details

Title Extensive Semi-Automated Gait Analysis by Zebris FDM during Treatment of Multiple Sclerosis Associated Gait Disturbancies with Fampridine-SR

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 102

Objective

Background BACKGROUND: The "sustained release" (SR)-formulation of fampridine has been approved for the treatment of multiple sclerosis (MS)-associated gait disorders. The pivotal trials showed a significant effect of fampridine-SR on the "Timed 25 Foot Walking Test". However, the relevance of this primary outcome measure on daily life has extensively been discussed.

Design/Methods DESIGN/METHODS: Zebris FDM is a gait analysis system which uses a 300 x 60 cm mat containing of more than 22500 pressure sensors. This analysis system is has been evaluated broadly and is therefore commonly applied by physiotherapists in rehabilitation centres. We included 20 patients with MS-associated gait disturbances (EDSS 4,0 to 7,0) and performed a semi-automated gait analysis by the aid of Zebris FDM to determine gait velocity and variability of gait velocity before and during fampridine-SR treatment.

Results RESULTS: Treatment with fampridine-SR led to a significant and for at least 6 months sustained improvement of gait velocity and variability of gait velocity in 10 out of 20 patients. 2 patients had to discontinue treatment due to side effects (nausea, headaches) despite of improvement. 7 patients showed no improvement after onset of fampridine-SR. 1 patient had to stop treatment due to vertigo before gait analysis. Both parameters (velocity and variability of velocity) obtained by semi-automated gait analysis correlated tightly with the "Timed 25 Foot Walking Test".

Conclusions CONCLUSIONS: Fampridine-SR had a measurable positive effect on MS-associated gait disturbances. In our study we were able to obtain positive effects on parameters measured by semi-automated gait analysis that have been shown to be relevant in daily life in patients with gait disturbances.

Authors/Disclosures
Barbara J. Holl, MD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Peter Wipfler	Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Eugen Trinka	Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rapport. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Eugen Trinka has received research support from European Union. Eugen Trinka has received publishing royalties from a publication relating to health care.
Bernhard Iglseder	No disclosure on file
Joerg R. Kraus, MD (Ordination Dr. Kraus)	No disclosure on file

��ɫ��

��ɫ��